- Email: [email protected]
Accepted Dental Remedies
COUNCIL ON DENTAL THERAPEUTICS ACCEPTED D E N T A L REMEDIES T he follow ing articles have been accepted as conform ing to the rules of the Council on Dental Therapeutics o f the American Dental Association. T he Council wishes dentists to understand that the admission o f an article does not imply a recommendation. A copy of the rules that govern the Council in the consideration o f articles w ill be sent on request. S a m u e l M . G o r d o n , Secretary
A N E S T H E T IC S — L O C A L * N ov oca in S olu tion 2 0 % w ith Suprarenin 1:9000: Each cubic centim eter contains novocain, 0.2 g m .; suprarenin (as bitartrate), 0.00011 g m .; sodium bisulphite, n ot m ore than 0.00S g m .; distilled w ater to make 1 c.c. T h is solution must be diluted b efore it is used. (O n e v o l ume, fo r exam ple, yields ten volum es o f a novocain solution, 2% , with suprarenin 1 :90,000.) Novocain Solution 20% with Suprarenin 1:9000 in Ampules, 1.5 c.c. Novocain Solution 20% with Suprarenin 1:9000 in Ampules, 5 c.c.
N ov oca in S olution 2 % w ith Suprarenin 1:20,000: Each cubic centimeter contains n ovocain, 0.02 g m .; suprarenin (as bitartrate), 0.00005 g m .; sodium chloride, 0.002 g m .; p o tassium sulphate, 0.004 g m .; sodium bisulphite, n ot m ore than 0.0015 g m .; distilled w ater to make 1 c.c. Novocain Solution 2% with Suprarenin 1:20,000 in Ampules, 1 c.c . Novocain Solution 2% with Suprarenin 1:20,000 in Ampules, 3 c.c. Novocain Solution 2% with Suprarenin 1:20,000 in Ampules, 6 c.c.
N o v o ca in S olu tion 2 % w ith Suprarenin 1:50,000: Each cubic centim eter contains n ovocain, 0.02 g m .; suprarenin (as bitartrate), 0.00002 g m .; sodium chloride, 0.002 g m .; potas sium sulphate, 0.004 g m .; sodium bisulphite, n ot m ore than 0.0015 g m .; distilled water to make 1 c.c. Novocain Solution 2% with Suprarenin 1:50,000 in Ampules, 1 c.c. Novocain Solution 2% with Suprarenin 1:50,000 in Ampules, 3 c.c.
N ovocain S olution 1 % w ith Suprarenin 1:50,000: E ach cubic centim eter contains novocain, 0.01 g m .; suprarenin (as bitartrate), 0.00002 g m .; sodium chloride, 0.004 g m .; potas sium sulphate, 0.004 g m .; sodium bisulphite, not m ore than 0.0015 g m .; distilled w ater to make 1 c.c. Novocain Solution 1% with Suprarenin 1:50,000 in Ampules, 2 c.c. Novocain Solution 1% with Suprarenin 1:50,000 in Ampules, 6 c.c.
N ovocain (0.125 G m .) and Suprarenin (0.125 M g .) H y p o d erm ic T ab lets: E ach tablet contains novocain, 0.125 g m .; suprarenin (as bitartrate), 0.000125 g m .; b oric acid, 0.00652 gm., and acetone sodium bisulphite, not m ore than 0.00025 gm. N ovocain (0.1 G m .) and Suprarenin (0.25 M g .) H y p o d er mic T ab lets: Each tablet contains novocain, 0.1 g m .; supra renin (as bitartrate), 0.00025 g m .; b oric acid, 0.00525 gm., and acetone sodium bisulphite, n ot m ore than 0.0002 gm. N ovocain (0.05 G m .) and Suprarenin (0.083 M g .) H y p o derm ic T a b lets: E ach tablet contains novocain, 0.05 g m .; suprarenin (as bitartrate), 0.000083 g m .; b oric acid, 0.00275 gm., and acetone sodium bisulphite, not m ore than 0.0001 gm. N ovocain (0.02 G m .) and Suprarenin (0.05 M g .) H yp od er•A.D.R., 1935, p. 43. Jour. A .D .A ., Vol. 23, M ay, 1936
899
900
The Journal of the American Dental Association m ic T ab lets: E ach tablet contains novocain, 0.02 g m .; suprarenin (as bitartrate), 0.00005 g m .; b oric acid, 0.00187 gm., and acetone sodium bisulphite, not m ore than 0.00004 gm. N ovocain (0.06 G m .) and Suprarenin (0.06 M g .) H y p o d er m ic T a b lets: E ach tablet contains novocain, 0.06 g m .; supra renin (as bitartrate), 0.00006 g m .; b oric acid, 0.003S7 gm., and acetone sodium bisulphite, n ot m ore than 0.00012 gm. N ov oca in (0.08 G m .) and Suprarenin (0.06 M g .) H y p o d er m ic T a b lets: E ach tablet contains novocain, 0.08 g m .; supra renin (as bitartrate), 0.00006 g m .; boric acid, 0.00473 gm., and acetone sodium bisulphite, not m ore than 0.00016 gm. N ovocain (0.02 G m .) and Suprarenin (0.02 M g .) H y p o d er mic T a b lets: E ach tablet contains novocain, 0.02 g m .; supra renin (as bitartrate), 0.00002 g m .; b oric acid, 0.001924 gm., and acetone sodium bisulphite, not m ore than 0.00004 gm. N ovocain (0.01 G m .) and Suprarenin (0.0002 G m .) P lu glets: E ach pluglet contains novocain, 0.01 g m .; suprarenin (as bitartrate), 0.0002 gm., and acetone sodium bisulphite, n ot m ore than 0.00002 gm. Manufactured by Winthrop Chemical Company, Inc., New York City.
DENTIFRICES* W illia m s ’ D e n ta l P o w d e r .— C om position : Each 100 gm. is stated to con ta in : calcium carbonate (S tu rge N o. 130), 85 g m .; castile soap, 12.5 g m .; saccharin, 0.1 g m .; flavor, 2.4 gm. A bra siven ess: 4.3 mg. per thousand revolutions (John & E. Sturge, Ltd., instrument). Manufactured and distributed by the J. B. Williams Company, Glastonbury, Conn. No U. S. patent or trademark.
ARSENIC COMPOUNDSf M a p h a rsen .— T h e hem ialcoholate of 3 -am ino-4-hydroxy phenyl-arsine ox id e hydrochloride.— H C l.(N H 2)C eH 3( O H ) A S O .I/ 2 C 2H 5O H . It contains approxim ately 29 per cent o f trivalent arsenic. P r o p e r t i e s : Mapharsen occurs as a white, amorphous, odorless pow der. It is soluble in water, alcohols, acids, alkalis and alkali car bonates. The aqueous solution is acid to methyl red, but alkaline to congo red. A ctions a n d U ses : M apharsen is proposed principally f o r the treatment o f syphilis. It is said to exhibit a relatively constant parasiticidal value. R eactions follow in g the use o f mapharsen have on the w h ole been less severe than those ob served after the use o f arsphenamine or neo-arsphenam ine in the treatment o f syphilis. It is claim ed to affect V in cent’ s infection fav ora b ly and quickly. It is directly and im m edi ately spirocheticidal and th erefore suitable fo r local applica tion. A fte r such application the spirochetes and fu s ifo rm bacilli disappear, w ith healing o f the lesions. D o s a g e : A pp lied locally as pow der o r in solution. Sixty milligrams is said to be sufficient fo r a single treatment. Manufactured by Parke, Davis & Co., Detroit, Mich. U. S. patent applied for. U. S. trademark 299,173. A m pou les M apharsen 0.04 G m .: Each contains mapharsen, 0.04 gm., anhydrous sodium carbonate, 0.008 gm., and anhy drous sucrose, 0.152 gm. A m pou les M apharsen 0.06 G m .: Each contains mapharsen, 0.06 gm., anhydrous sodium carbonate, 0.012 gm., and anhy drous sucrose, 0.228 gm. O ther tests o f identity, purity and assay appear in the J ou r nal o f the A m erican M ed ical A ssociation, Tan. 18, 1936, pp. 106-214. ‘ A.D.R., 1935, p. 91. ÍA.D.R., 1935, p. 50.
A N E S T H E T IC S — L O C A L * N ov oca in S olu tion 2 0 % w ith Suprarenin 1:9000: Each cubic centim eter contains novocain, 0.2 g m .; suprarenin (as bitartrate), 0.00011 g m .; sodium bisulphite, n ot m ore than 0.00S g m .; distilled w ater to make 1 c.c. T h is solution must be diluted b efore it is used. (O n e v o l ume, fo r exam ple, yields ten volum es o f a novocain solution, 2% , with suprarenin 1 :90,000.) Novocain Solution 20% with Suprarenin 1:9000 in Ampules, 1.5 c.c. Novocain Solution 20% with Suprarenin 1:9000 in Ampules, 5 c.c.
N ov oca in S olution 2 % w ith Suprarenin 1:20,000: Each cubic centimeter contains n ovocain, 0.02 g m .; suprarenin (as bitartrate), 0.00005 g m .; sodium chloride, 0.002 g m .; p o tassium sulphate, 0.004 g m .; sodium bisulphite, n ot m ore than 0.0015 g m .; distilled w ater to make 1 c.c. Novocain Solution 2% with Suprarenin 1:20,000 in Ampules, 1 c.c . Novocain Solution 2% with Suprarenin 1:20,000 in Ampules, 3 c.c. Novocain Solution 2% with Suprarenin 1:20,000 in Ampules, 6 c.c.
N o v o ca in S olu tion 2 % w ith Suprarenin 1:50,000: Each cubic centim eter contains n ovocain, 0.02 g m .; suprarenin (as bitartrate), 0.00002 g m .; sodium chloride, 0.002 g m .; potas sium sulphate, 0.004 g m .; sodium bisulphite, n ot m ore than 0.0015 g m .; distilled water to make 1 c.c. Novocain Solution 2% with Suprarenin 1:50,000 in Ampules, 1 c.c. Novocain Solution 2% with Suprarenin 1:50,000 in Ampules, 3 c.c.
N ovocain S olution 1 % w ith Suprarenin 1:50,000: E ach cubic centim eter contains novocain, 0.01 g m .; suprarenin (as bitartrate), 0.00002 g m .; sodium chloride, 0.004 g m .; potas sium sulphate, 0.004 g m .; sodium bisulphite, not m ore than 0.0015 g m .; distilled w ater to make 1 c.c. Novocain Solution 1% with Suprarenin 1:50,000 in Ampules, 2 c.c. Novocain Solution 1% with Suprarenin 1:50,000 in Ampules, 6 c.c.
N ovocain (0.125 G m .) and Suprarenin (0.125 M g .) H y p o d erm ic T ab lets: E ach tablet contains novocain, 0.125 g m .; suprarenin (as bitartrate), 0.000125 g m .; b oric acid, 0.00652 gm., and acetone sodium bisulphite, not m ore than 0.00025 gm. N ovocain (0.1 G m .) and Suprarenin (0.25 M g .) H y p o d er mic T ab lets: Each tablet contains novocain, 0.1 g m .; supra renin (as bitartrate), 0.00025 g m .; b oric acid, 0.00525 gm., and acetone sodium bisulphite, n ot m ore than 0.0002 gm. N ovocain (0.05 G m .) and Suprarenin (0.083 M g .) H y p o derm ic T a b lets: E ach tablet contains novocain, 0.05 g m .; suprarenin (as bitartrate), 0.000083 g m .; b oric acid, 0.00275 gm., and acetone sodium bisulphite, not m ore than 0.0001 gm. N ovocain (0.02 G m .) and Suprarenin (0.05 M g .) H yp od er•A.D.R., 1935, p. 43. Jour. A .D .A ., Vol. 23, M ay, 1936
899
900
The Journal of the American Dental Association m ic T ab lets: E ach tablet contains novocain, 0.02 g m .; suprarenin (as bitartrate), 0.00005 g m .; b oric acid, 0.00187 gm., and acetone sodium bisulphite, not m ore than 0.00004 gm. N ovocain (0.06 G m .) and Suprarenin (0.06 M g .) H y p o d er m ic T a b lets: E ach tablet contains novocain, 0.06 g m .; supra renin (as bitartrate), 0.00006 g m .; b oric acid, 0.003S7 gm., and acetone sodium bisulphite, n ot m ore than 0.00012 gm. N ov oca in (0.08 G m .) and Suprarenin (0.06 M g .) H y p o d er m ic T a b lets: E ach tablet contains novocain, 0.08 g m .; supra renin (as bitartrate), 0.00006 g m .; boric acid, 0.00473 gm., and acetone sodium bisulphite, not m ore than 0.00016 gm. N ovocain (0.02 G m .) and Suprarenin (0.02 M g .) H y p o d er mic T a b lets: E ach tablet contains novocain, 0.02 g m .; supra renin (as bitartrate), 0.00002 g m .; b oric acid, 0.001924 gm., and acetone sodium bisulphite, not m ore than 0.00004 gm. N ovocain (0.01 G m .) and Suprarenin (0.0002 G m .) P lu glets: E ach pluglet contains novocain, 0.01 g m .; suprarenin (as bitartrate), 0.0002 gm., and acetone sodium bisulphite, n ot m ore than 0.00002 gm. Manufactured by Winthrop Chemical Company, Inc., New York City.
DENTIFRICES* W illia m s ’ D e n ta l P o w d e r .— C om position : Each 100 gm. is stated to con ta in : calcium carbonate (S tu rge N o. 130), 85 g m .; castile soap, 12.5 g m .; saccharin, 0.1 g m .; flavor, 2.4 gm. A bra siven ess: 4.3 mg. per thousand revolutions (John & E. Sturge, Ltd., instrument). Manufactured and distributed by the J. B. Williams Company, Glastonbury, Conn. No U. S. patent or trademark.
ARSENIC COMPOUNDSf M a p h a rsen .— T h e hem ialcoholate of 3 -am ino-4-hydroxy phenyl-arsine ox id e hydrochloride.— H C l.(N H 2)C eH 3( O H ) A S O .I/ 2 C 2H 5O H . It contains approxim ately 29 per cent o f trivalent arsenic. P r o p e r t i e s : Mapharsen occurs as a white, amorphous, odorless pow der. It is soluble in water, alcohols, acids, alkalis and alkali car bonates. The aqueous solution is acid to methyl red, but alkaline to congo red. A ctions a n d U ses : M apharsen is proposed principally f o r the treatment o f syphilis. It is said to exhibit a relatively constant parasiticidal value. R eactions follow in g the use o f mapharsen have on the w h ole been less severe than those ob served after the use o f arsphenamine or neo-arsphenam ine in the treatment o f syphilis. It is claim ed to affect V in cent’ s infection fav ora b ly and quickly. It is directly and im m edi ately spirocheticidal and th erefore suitable fo r local applica tion. A fte r such application the spirochetes and fu s ifo rm bacilli disappear, w ith healing o f the lesions. D o s a g e : A pp lied locally as pow der o r in solution. Sixty milligrams is said to be sufficient fo r a single treatment. Manufactured by Parke, Davis & Co., Detroit, Mich. U. S. patent applied for. U. S. trademark 299,173. A m pou les M apharsen 0.04 G m .: Each contains mapharsen, 0.04 gm., anhydrous sodium carbonate, 0.008 gm., and anhy drous sucrose, 0.152 gm. A m pou les M apharsen 0.06 G m .: Each contains mapharsen, 0.06 gm., anhydrous sodium carbonate, 0.012 gm., and anhy drous sucrose, 0.228 gm. O ther tests o f identity, purity and assay appear in the J ou r nal o f the A m erican M ed ical A ssociation, Tan. 18, 1936, pp. 106-214. ‘ A.D.R., 1935, p. 91. ÍA.D.R., 1935, p. 50.